Skip to content
Screener

Fulgent Genetics, Inc. FLGT Laboratory Services — Allocated Share Based Compensation Expense

Other segment segments

Therapeutic Development
$2.25M+11.5%

Similar metrics at other companies

Nutanix, Inc. logo
NTNXService — Allocated Share Based Compensation Expense
$5.71M-13.8%
LENSAR, Inc. logo
LNSRService — Allocated Share Based Compensation Expense
$56K+75.0%
HubSpot logo
HUBSService — Allocated Share Based Compensation Expense
$646K-38.5%
Netscout Systems logo
NTCTService — Allocated Share Based Compensation Expense
$2.71M-1.2%
Vertex, Inc. logo
VERXService Other — Allocated Share Based Compensation Expense
$1.67M-1.5%
SS&C Technologies logo
SSNCSoftware Enabled Services — Allocated Share Based Compensation Expense
$20.7M+19.0%

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation

See full
Market cap$526.64M-16.5%
Enterprise value$511.45M-6.7%
P/S1.6×-0.4×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0.0×
Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 7:08 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-199065
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Equity-based compensation
Laboratory services$7,640$8,532
Therapeutic development2,2502,018
Total$9,890$10,550

Item 1. Financial Statements.

FAQ

What is Fulgent Genetics, Inc.'s laboratory services — allocated share based compensation expense?
Fulgent Genetics, Inc. (FLGT) reported laboratory services — allocated share based compensation expense of $7.64M in Q1 2026.
How has Fulgent Genetics, Inc.'s laboratory services — allocated share based compensation expense changed year-over-year?
Fulgent Genetics, Inc.'s laboratory services — allocated share based compensation expense decreased by 10.5% year-over-year, from $8.53M to $7.64M.
What is the long-term trend for Fulgent Genetics, Inc.'s laboratory services — allocated share based compensation expense?
Over 3 years (2022 to 2025), Fulgent Genetics, Inc.'s laboratory services — allocated share based compensation expense has grown at a -1.1% compound annual growth rate (CAGR), from $32.64M to $31.57M.
What does laboratory services — allocated share based compensation expense mean?
This represents the portion of total share-based compensation costs attributed to employees working within the laboratory services segment. It is a non-cash expense that reflects the cost of equity-based incentives used to attract and retain talent in the laboratory operations.

Ask your AI about Fulgent Genetics, Inc.'s laboratory services — allocated share based compensation expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude